5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Market is segmented by Product (Cell Lines, Reagents and Kits, Microplates, Other Consumables), Technology, Application, End-user and Geography
Fastest Growing Market:
The cell-based assay market will show rapid growth due to the rising prevalence of chronic diseases and lifestyle disorders, increasing investments in R&D for drug discovery and the rise in technological advancements in cell-based methodologies.
The rising prevalence of chronic diseases and lifestyle disorders, such as cancer, cardiovascular, diabetes, and neurological disorders is one of the primary factors fueling the market growth. According to the WHO, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. It has been calculated that, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of NCDs is expected to increase to 57% by 2020.
Almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity and diabetes are also showing increasing trends. Thus, the rise in chronic diseases leads to demand growth for cell-based assays for new drug discoveries, making it a vital factor for market growth. In addition, the demand for cell-based assay has increased significantly owing to a surge in cell-based applications in drug discovery and the rise in technological advancements in cell-based assays methodologies.
As per the scope of the report, cell-based assays are versatile research lab tools used in healthcare. These tools are designed to target specific cells by using antibodies or other moieties, to determine the functionality and efficacy of drugs. Also, cell-based assays help to measure cell motility, proliferation and facilitate research in the area of stem cells, immunology, cancer, and others.
|Reagents and Kits|
|Academic & Government Institutes|
|Pharmaceutical and Biotechnology Companies|
Report scope can be customized per your requirements. Click here.
The drug discovery segment is anticipated to show high growth in the market and this growth can be attributed to the increase in the R&D investment by biopharmaceutical companies. In addition, the rise in the prevalence of chronic diseases, such as cancer, osteoarthritis, cardiovascular diseases, and diabetes, is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market. In cell-based assays, functional cells are used as diagnostic tools in research for new drugs that help in drug discovery.
To understand key trends, Download Sample Report
North America is the leading region across the world in terms of market share owing to the well-established healthcare sector along with the high adoption of cell-based therapies. In the United States, the prevalence of chronic diseases, such as cancer, osteoarthritis, and diabetes, is increasing that is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market.
Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC region is largely driven by the increasing R&D investment by the government and increasing infrastructural development in the region.
To understand geography trends, Download Sample Report.
The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., and Promega Corporation. Product innovation and ongoing R&D activities to develop advanced technologies have helped in boosting the growth of the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.2 Increasing Investments in R&D for Drug Discovery
4.2.3 Rise in Technological Advancements in Cell-based Methodologies
4.3 Market Restraints
4.3.1 High Maintenance and Operational Costs
4.3.2 Lack of Skilled Personnel to Operate these Technologies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.1.1 Cell Lines
220.127.116.11 Primary Cell Lines
18.104.22.168 Stem Cell Lines
5.1.2 Reagents and Kits
5.1.4 Other Consumables
5.2 By Technology
5.2.1 Automated Handling
5.2.2 Flow Cytometry
5.2.3 Label-free Detection
5.2.4 High-throughput Screening
5.3 By Application
5.3.1 Drug Discovery
5.3.2 Other Applications
5.4 By End-user
5.4.1 Academic & Government Institutes
5.4.2 Pharmaceutical and Biotechnology Companies
5.5.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.5.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Corning Inc.
6.1.4 Danaher Corporation
6.1.5 Thermo Fisher Scientific Inc.
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Merck KGaA
6.1.8 Perkin Elmer Inc.
6.1.9 Promega Corporation
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments